Early versus delayed evolocumab treatment and complex coronary artery revascularization

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Clinical Trials

Background:

• The FOURIER trial demonstrated that evolocumab (a PCSK9 inhibitor) significantly reduced major adverse cardiovascular events.
• Evolocumab targets low-density lipoprotein cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease (ASCVD).

Purpose of the Study:

• To evaluate the long-term impact of evolocumab on complex coronary revascularization.
• Investigate the benefits of early versus delayed initiation of evolocumab therapy.

Main Methods:

• Patients with ASCVD and elevated LDL-C despite statin therapy were randomized to evolocumab or placebo in the FOURIER trial.
• A subset continued to an open-label extension (OLE), allowing comparison of early versus delayed evolocumab treatment over 8 years.
• Complex revascularization was defined using the GLOBAL LEADERS criteria (coronary artery bypass graft surgery or complex percutaneous coronary intervention).

Main Results:

• Early evolocumab treatment reduced complex coronary revascularization by 24% over 8 years (HR 0.76).
• Significant reductions were observed for both coronary artery bypass graft surgery (HR 0.77) and complex percutaneous coronary intervention (HR 0.78).
• Early treatment also led to a reduction in total stent length implanted.

Conclusions:

• Early and sustained treatment with evolocumab significantly lowers the risk of complex coronary revascularization.
• Initiating evolocumab earlier in ASCVD patients provides long-term benefits in reducing the need for complex procedures.